SCHEMBL145545

SCHEMBL145545

CN1CCCC1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163401 1.00
SCHEMBL77336 1.00
Hydrochloric Acid SCHEMBL113877 0.98 ACE (0.46)
Water SCHEMBL2694310 0.98 ACE (0.46)
Bromide SCHEMBL6632312 0.98 ACE (0.46)
Water SCHEMBL1598128 0.98 ACE (0.46)
Hydrochloric Acid SCHEMBL113878 0.98 ACE (0.46)
Water SCHEMBL1598131 0.98 ACE (0.46)
Hydrochloric Acid SCHEMBL1721046 0.98 ACE (0.46)
SCHEMBL26612359 0.98 ACE (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2133 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MARVELBIOME INC (US) 2026-04-02 US claimed
US-20250361490-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA CELLVIE AG (CH) 2025-11-27 US claimed
EP-4615837-A1 USEFUL COMPOUNDS FOR MODULATING INFLAMMATION Flagship Pioneering Innovations VI, LLC (US) 2025-09-17 EP claimed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP claimed
US-20250147048-A1 METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2025-05-08 US claimed
EP-4535996-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA cellvie AG (CH) 2025-04-16 EP claimed
WO-2025054048-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS MarvelBiome, Inc. (US) 2025-03-13 WO claimed
CN-119365073-A Compositions and methods for cryopreserving mitochondria 赛立维公司 2025-01-24 CN claimed
CN-119177441-A Nonferrous metal electroplating material and preparation process thereof 深圳市生利科技有限公司 2024-12-24 CN claimed
WO-2024239704-A1 SOLAR CELL, SOLAR CELL MODULE, AND ELECTRIC DEVICE 宁德时代新能源科技股份有限公司 2024-11-28 WO claimed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 US claimed
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2003-08-14 US claimed
WO-2003048106-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2003-06-12 WO claimed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 WO claimed
US-20020198156-A1 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2002-12-26 US claimed
WO-2002074050-A2 ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2002-09-26 WO claimed
US-5665371-A SIDE EFFECT REDUCTION HOERRMANN WILHELM (DE) 1997-09-09 US claimed
EP-0422937-B1 Fibrinogen receptor antagonists MERCK & CO INC (US) 1994-03-02 EP claimed
EP-0422937-A1 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1991-04-17 EP claimed
US-4336249-A MYCOPLANECIN PRODUCT CULTIVATED FORM ACTINOPLANES SANKYO COMPANY LIMITED (JP) 1982-06-22 US claimed